Drugmaker AstraZeneca said it intends to cap out-of-pocket prices of four medicines used to treat asthma and chronic obstructive pulmonary disease (COPD) to $35 per month for many patients. Starting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results